MedTrace Logo

Outcomes of Proactive Management of Children With Myelomeningocele

NCT06301802 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-03-08

No results posted yet for this study

Summary

Spina bifida birth prevalence in Africa is 0.13%. Myelomeningocele (MMC) represents the most frequent and most severe cause of NB in children. Treatment of neuropathic bladder secondary to spina bifida is an ongoing challenge. Damage of the renal parenchyma in children with NB is preventable given adequate evaluation, follow-up and proactive management. Proactive management was defined as use of clean intermittent catheterization (CIC), and/or anticholinergics at presentation, or based on initial high-risk urodynamic findings by 1 year of age. The proactive approach to treat SB (CIC and pharmacotherapy) has contributed to decreasing chronic kidney disease (CKD). Myelomeningocele is considered a complex congenital disease. Hence, a multidisciplinary team is the best choice for management of spina bifida, involving neurosurgeons, orthopedic surgeons, urologists, physical medicine and rehabilitation specialists and pediatricians. Currently, children with spina bifida in Egypt must visit multiple different locations to access the complex care they need. Here, we review our experience with patients with spina bifida who will be followed with this team with an emphasis on patients' upper urinary tract protection and decreasing urinary incontinence.

Conditions

  • Urologic Diseases

Interventions

PROCEDURE

CIC

clean intermittent catheterization

DRUG

Anticholinergic

antimuscarinic once daily

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahmad Elderwy, prof · prof of urology assiut university

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-04
Primary Completion
2026-03-10
Completion
2026-03-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06301802 on ClinicalTrials.gov